SummaryAnhui Gute Biotechnology Co., Ltd., also identified as Anhui GSH Bio-Technology Co., Ltd., is a China-based manufacturing company established in 2017. It reports three production lines, production bases in Jilin and Anhui, a third base planned for construction in 2023, 20 years of combined R&D engineer experience, and 21–30 quality-control staff. Its listed products include glutathione, NMN, citicoline sodium, CoQ10, and related ingredients, with stated output for several products. The supplier reports ISO9001:2015 and applications for BRCGS, HALAL, KOSHER, FSSC, HACCP, and FDA-related certifications. An SGS audit record is valid from June 20, 2025 to June 19, 2026, but the provided audit result value is not interpretable as a performance conclusion. Overseas service, detailed R&D services, customization, sustainability systems, and customer cases remain insufficiently evidenced.
Supplier typeThe supplier is explicitly identified as a factory and manufacturing enterprise in Anhui, China, with production bases in Anhui and Jilin and an integrated R&D, production, and sales model. This supports classification as a direct manufacturer rather than a trading-only entity.
CertificationsThe supplier explicitly reports an ISO9001:2015 certificate and lists applications for BRCGS, HALAL, KOSHER, FSSC, HACCP, and FDA-related certificates. An SGS audit record is also shown as valid from June 20, 2025 to June 19, 2026, although the supplied audit result value does not establish the audit outcome.
R&D capabilityThe supplier describes integrated R&D, production, and sales, 14 years of R&D experience, 19 declared Chinese invention patents, 2 declared international invention patents, 7 authorized Chinese invention patents, and 8 software copyrights. Nevertheless, specific professional-technical R&D, 3D design, SDK, new-product, and ODM capabilities are marked unknown.
Production capacityThe supplier reports three production lines, major production bases in Jilin and Anhui, a third base planned to begin construction in April 2023, and product output figures for citicoline sodium, glutathione, and NMN. These records provide explicit evidence of established production capacity and multi-site operations.